Patrick C O’Connor, FRCP (Edin), Ph.D. (Chairman)
CMO, Lakewood-Amedex and Managing Director, Strategic Clinical Development, Auven Therapeutics|
Dr. Patrick C. O’Connor has more than 30 years of pharmaceutical/device product development in the U.S., Europe and Japan. Dr. O’Connor graduated in medicine and after his internship he spent six years in Basic Physiology and Pharmacology research at University College, Cork, Ireland and Manchester University in the U.K. leading to a Ph.D. He worked for ten years in the British National Health Service at various academic centers. Dr. O’Connor is a registered specialist in the U.K., with accreditation in Internal Medicine and Clinical Pharmacology.
Since 2012 he has been Managing Director, Strategic Clinical Development for Auven Therapeutics, a hybrid private equity fund. Prior, he held senior positions at Boots Pharmaceuticals, Pharmaco, PPD, Ferring Group of Companies and Celtic Pharma. Over the course of his career Dr. O’Connor has been intimately involved in product development across a wide variety of therapeutic areas with particular emphasis on managing external vendors.
Steven Petrou, M.D.
Senior Urologist, Mayo Clinic
Steven P. Petrou, MD is a practicing urologist in Jacksonville, Florida. Graduating from Vanderbilt University School of Medicine in 1984, Dr. Petrou has been in practice for more than 33 years. Previously serving as Chief of Surgery at St. Luke’s Hospital, he currently practices at Mayo Clinic.
Harvey Schonwald, M.D.
Practicing Urologist, Brooksville Hospital
Dr. Harvey Schonwald is a certified urologist in Spring Hill, Florida, and is affiliated with multiple hospitals in the area, including Bayfront Health Brooksville and Oak Hill Hospital. He graduated from the University of Maryland School of Medicine in 1974, earning honors in urology. After serving two years as a resident in general surgery at the Kaiser Foundation Hospital in San Francisco, he went on to train in urology for three years as a resident at the University of Maryland. Dr. Schonwald went into private practice in 1979, and was the Chief of Urology at St. Agnes Hospital in Baltimore, MD before relocating to Florida. He is board certified by the American Urologic Association and is a Fellow of the American College of Surgeons.
Former Research Defense Scientist, Defense R&D Canada
Jonathan “J.P.” Wong is a research scientist with more than 30 years of experience in the infectious disease and molecular biology spaces, having published more than 100 journal and conference papers during his career. Upon completion of his undergraduate and graduate studies in Biochemistry from University of Saskatchewan, Canada, he joined Defence R&D Canada – Suffield (DRDC Suffield) in 1985. While there, his work was focused in the experimental evaluation and development of novel antimicrobial drugs and vaccines against highly pathogenic infectious agents. His other major areas of research include drug and vaccine development, drug delivery systems, medical countermeasures against biological agents, development of novel prophylaxis and treatment against influenza virus infection, respiratory infections and aerosol delivery of drugs and vaccines.
Michael Schurr, MD
General Surgery and Critical Care
Prof. Michael Schurr, MD is a burn and trauma surgeon and general surgeon at Mission Hospitals, Asheville, NC. Dr. Schurr is board certified in general surgery and surgical critical care. He has joined Mission Hospitals as Director of Inpatient Surgical Wound Care in Dec 2014. Prior to that he practiced for more than 15 years at the School of Medicine in University of Wisconsin-Madison and University of Colorado-Denver. He brings 27 years of experience in advanced care of chronic ulcers, burns and trauma wounds. He has successfully led clinical trials of several advanced wound dressings and hernia surgical meshes.
Alfonso Ansi, MD
Previous Head of Clinical Development, Eli Lilly
Michael Silverman, MD
Infectious Disease Consultant
David Ng, PhD
Statistician with Expertise in Adaptive Designs
David pursued his chemistry studies at the National University of Singapore and received his B.Sc. degree with first class honors in 2009. In 2010, he accepted a scholarship offered by the Max Planck Institute for Polymer Research and moved with Prof. Dr. Tanja Weil to Ulm to work on developing dendritic biohybrids as precise nanotransporters for biomedical applications, focusing on organic chemistry and macromolecular design. David received his doctorate with summa cum laude in 2014 and thereafter worked as a group leader in the Institute of Organic Chemistry III at Ulm University until 2016. Since 2016, he leads the adaptive polymeric materials group at the Max Planck Institute for Polymer Research to develop synthetic macromolecular strategies into smart nanotherapeutics.